Photo from Cancer Research Communications/X
May 22, 2024, 01:03
Nicholas Hornstein: The first trial to demonstrate benefit of systemic therapy in appendiceal cancer
Nicholas Hornstein, Oncology Fellow at MD Anderson Cancer Centre, shared a post by Cancer Research Communications on X, adding:
“Pleased to announce the first trial to demonstrate benefit of systemic therapy in appendiceal cancer. Atezolizumab and Bevacizumab; significantly improved PFS compared to synthetic cohort.
Median PFS 18.3 vs 4.4 months. Thanks to John Paul Shen and Kanwal Raghav for mentorship.” .
Quoting Cancer Research Communications’ post:
“Just published: Efficacy and safety of atezolizumab and bevacizumab in appendiceal adenocarcinoma, by Nicholas Hornstein et al.”
Source: Nicholas Hornstein/X and Cancer Research Communications/X